Contact Information: GLOBEIMMUNE CONTACT: Kirk Christoffersen Senior Director, Corporate Development GlobeImmune, Inc. T: 303-625-2700 C: 303-775-7666 Email Contact
GlobeImmune CEO to Present at JPMorgan Healthcare Conference
| Source: GlobeImmune, Inc.
LOUISVILLE, CO -- (MARKET WIRE) -- January 3, 2007 -- GlobeImmune, Inc. announced today that
President and Chief Executive Officer, Timothy C. Rodell, M.D., will
present at the JPMorgan Healthcare Conference at the Westin St. Francis
Hotel in San Francisco at 9:30 a.m. PST on Thursday, January 11, 2007.
About GlobeImmune, Inc.
GlobeImmune is a biopharmaceutical company pioneering the discovery,
development, and manufacturing of potent, targeted molecular
immunotherapies called Tarmogens® for the treatment of cancer and
infectious diseases. GI-5005, GlobeImmune's lead product for the treatment
of chronic hepatitis C infection, is currently finishing a phase 1b trial
in which interim data for the first four dose cohorts have been analyzed
and show both safety and positive clinical responses. Additionally, GI-4000
for the treatment of mutated Ras-mediated cancers is currently in a phase 2
clinical trial for the treatment of pancreas cancer.
About Tarmogens
Tarmogens® (Targeted molecular immunogens) are whole, heat-killed S.
cerevisiae yeast, genetically modified to express high concentrations of
one or more disease-related proteins. Tarmogens are designed to reprogram
the human immune system to eliminate disease cells by linking the body's
innate immune response (a non-specific danger response) with an
antigen-specific T cell response. Because Tarmogens look dangerous to the
immune system, they initiate a chain of events that end with presentation
of disease-specific antigens and activation of both helper and killer T
cells. The Tarmogen platform has been shown to be active and well
tolerated in clinical trials in both cancer and infectious disease.
For additional information, please visit the company's website at
www.globeimmune.com.
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including statements relating
to the efficacy of the Company's technology and initiation, progress, and
results of the Company's clinical trial programs. Actual results could
differ materially from those projected and the Company cautions readers not
to place undue reliance on the forward-looking statements contained in the
presentation.